SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the 2018 Cantor Global Healthcare Conference in New York on Monday, October 1 at 3:30 p.m. ET/12:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will provide a corporate overview.
A live audio webcast of the presentation will be available in the "Investors" section of Halozyme's website at www.halozyme.com with an archived replay available for 90 days following the event.
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for the treatment of several cancers and has the potential to be used in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
Robert H. Uhl
Westwicke Partners, LLC
SOURCE Halozyme Therapeutics, Inc.